UGT2B15 and prostate cancer: Elevated circulating testosterone has been associated with UGT2B28 nuclear staining which may decrease expression of UGT2B15 and UGT2B17 since studies show that their expression is elevated in patients and prostate cancer cell cultures treated with antiandrogens [21, 22].